Patrick W. Smith - 26 Dec 2024 SCHEDULE 13G/A Report for OncoCyte Corp Common Stock, no par value (OCX)

Filing Manager
Patrick W. Smith
Reporting Manager
Patrick W. Smith
Symbol
OCX
Shares outstanding
16,894,314 shares
Disclosed Ownership
1,773,903 shares
Ownership
10%
Form type
SCHEDULE 13G/A
Filing time
27 Dec 2024, 21:58:27 UTC
Date of event
26 Dec 2024

Key filing fact

Patrick W. Smith disclosed 10% ownership in OncoCyte Corp Common Stock, no par value (OCX) on 26 Dec 2024.

Key facts

  • Patrick W. Smith filed SCHEDULE 13G/A for OncoCyte Corp Common Stock, no par value (OCX).
  • Disclosed ownership: 10%.
  • Date of event: 26 Dec 2024.

Change

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 27 Dec 2024, 21:58.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (2)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Patrick W. Smith 10% 1,773,903 0 1,773,903 /s/ Patrick W. Smith Patrick W. Smith, individually
PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 10% 1,773,903 0 1,773,903 /s/ Patrick W. Smith Patrick W. Smith/Trustee
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .